Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 20398370)

  • 1. Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab.
    Campanella C; Mottolese M; Cianciulli A; Torsello A; Merola R; Sperduti I; Melucci E; Conti S; Diodoro MG; Zeuli M; Paoletti G; Cognetti F; Garufi C
    J Transl Med; 2010 Apr; 8():36. PubMed ID: 20398370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant.
    Molinari F; Martin V; Saletti P; De Dosso S; Spitale A; Camponovo A; Bordoni A; Crippa S; Mazzucchelli L; Frattini M
    Br J Cancer; 2009 Apr; 100(7):1087-94. PubMed ID: 19293803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial.
    Ouchi K; Takahashi S; Sasaki K; Yoshida Y; Taniguchi S; Kasahara Y; Komine K; Imai H; Saijo K; Shirota H; Takahashi M; Ishioka C
    Int J Colorectal Dis; 2024 Jun; 39(1):89. PubMed ID: 38862615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC.
    Hirsch FR; Redman MW; Moon J; Agustoni F; Herbst RS; Semrad TJ; Varella-Garcia M; Rivard CJ; Kelly K; Gandara DR; Mack PC
    Clin Lung Cancer; 2022 Jan; 23(1):60-71. PubMed ID: 34753703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324.
    Komaki R; Paulus R; Blumenschein GR; Curran WJ; Robert F; Thariat J; Werner-Wasik M; Choy H; Hirsch FR; Ang KK
    Radiother Oncol; 2014 Jul; 112(1):30-6. PubMed ID: 25042878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy plus targeted drugs in conversion therapy for potentially resectable colorectal liver metastases: a meta-analysis.
    Wang L; Sun Y; Zhao B; Zhang H; Yu Q; Yuan X
    Oncotarget; 2016 Aug; 7(34):55732-55740. PubMed ID: 27248177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR 20th Anniversary Commentary: RAS as a Biomarker for EGFR--Targeted Therapy for Colorectal Cancer-From Concept to Practice.
    Camp ER; Ellis LM
    Clin Cancer Res; 2015 Aug; 21(16):3578-80. PubMed ID: 26275951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819.
    Redman MW; Crowley JJ; Herbst RS; Hirsch FR; Gandara DR
    Clin Cancer Res; 2012 Aug; 18(15):4004-12. PubMed ID: 22592956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in Epidermal Growth Factor Receptor Gene Copy Number during Oral Carcinogenesis.
    Bates T; Kennedy M; Diajil A; Goodson M; Thomson P; Doran E; Farrimond H; Thavaraj S; Sloan P; Kist R; Robinson M
    Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):927-35. PubMed ID: 27197272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort.
    Smith DH; Christensen IJ; Jensen NF; Markussen B; Rømer MU; Nygård SB; Müller S; Nielsen HJ; Brünner N; Nielsen KV
    PLoS One; 2013; 8(4):e60613. PubMed ID: 23577133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and prognostic analysis of the cetuximab resistance-related gene
    Zhu N; Fang X; Li D; Yang M; Zhu L; Zhong L; Weng S; Wang J; Yuan Y
    Am J Cancer Res; 2021; 11(6):2769-2781. PubMed ID: 34249427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.
    Cengel KA; Voong KR; Chandrasekaran S; Maggiorella L; Brunner TB; Stanbridge E; Kao GD; McKenna WG; Bernhard EJ
    Neoplasia; 2007 Apr; 9(4):341-8. PubMed ID: 17460778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer.
    Cohen AS; Geng L; Zhao P; Fu A; Schulte ML; Graves-Deal R; Washington MK; Berlin J; Coffey RJ; Manning HC
    Transl Oncol; 2020 Oct; 13(10):100828. PubMed ID: 32652471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.
    Rivera M; Fichtner I; Wulf-Goldenberg A; Sers C; Merk J; Patone G; Alp KM; Kanashova T; Mertins P; Hoffmann J; Stein U; Walther W
    Neoplasia; 2021 Jan; 23(1):21-35. PubMed ID: 33212364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS.
    Liu J; Hu J; Cheng L; Ren W; Yang M; Liu B; Xie L; Qian X
    Onco Targets Ther; 2016; 9():557-65. PubMed ID: 26869800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2.
    Boeckx N; Peeters M; Van Camp G; Pauwels P; Op de Beeck K; Deschoolmeester V
    Drugs; 2015 Oct; 75(15):1739-56. PubMed ID: 26347132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.
    Shen WD; Chen HL; Liu PF
    Chin J Cancer Res; 2014 Feb; 26(1):59-71. PubMed ID: 24653627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis.
    Jiang Z; Li C; Li F; Wang X
    PLoS One; 2013; 8(2):e56205. PubMed ID: 23441167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR status and KRAS/BRAF mutations in intestinal-type sinonasal adenocarcinomas.
    García-Inclán C; López F; Pérez-Escuredo J; Cuesta-Albalad MP; Vivanco B; Centeno I; Balbín M; Suárez C; Llorente JL; Hermsen MA
    Cell Oncol (Dordr); 2012 Dec; 35(6):443-50. PubMed ID: 23055340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis.
    Yang ZY; Shen WX; Hu XF; Zheng DY; Wu XY; Huang YF; Chen JZ; Mao C; Tang JL
    J Hematol Oncol; 2012 Aug; 5():52. PubMed ID: 22897982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.